Himmelfarb Health Sciences Library, The George Washington University

Health Sciences Research Commons
Medicine Faculty Publications

Medicine

11-1-2021

Relationship of age, atherosclerosis and angiographic stenosis
using artificial intelligence.
Rebecca Jonas
James Earls
Hugo Marques
Hyuk-Jae Chang
Jung Hyun Choi

See next page for additional authors

Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/smhs_medicine_facpubs
Part of the Medicine and Health Sciences Commons

APA Citation
Jonas, R., Earls, J., Marques, H., Chang, H., Choi, J., Doh, J., Her, A., Koo, B., Nam, C., Park, H., Shin, S., Cole,
J., Gimelli, A., Khan, M., Lu, B., Gao, Y., Nabi, F., Nakazato, R., Schoepf, U., Driessen, R., Bom, M., Thompson,
R., Jang, J., Ridner, M., Rowan, C., Avelar, E., Généreux, P., Knaapen, P., de Waard, G., Pontone, G., Andreini,
D., Al-Mallah, M., Jennings, R., Crabtree, T., Villines, T., Min, J., & Choi, A. D. (2021). Relationship of age,
atherosclerosis and angiographic stenosis using artificial intelligence.. Open Heart, 8 (2).
http://dx.doi.org/10.1136/openhrt-2021-001832

This Journal Article is brought to you for free and open access by the Medicine at Health Sciences Research
Commons. It has been accepted for inclusion in Medicine Faculty Publications by an authorized administrator of
Health Sciences Research Commons. For more information, please contact hsrc@gwu.edu.

Authors
Rebecca Jonas, James Earls, Hugo Marques, Hyuk-Jae Chang, Jung Hyun Choi, Joon-Hyung Doh, AeYoung Her, Bon Kwon Koo, Chang-Wook Nam, Hyung-Bok Park, Sanghoon Shin, Jason Cole, Alessia
Gimelli, Muhammad Akram Khan, Bin Lu, Yang Gao, Faisal Nabi, Ryo Nakazato, U Joseph Schoepf, Roel S
Driessen, Michiel J Bom, Randall C Thompson, James J Jang, Michael Ridner, Chris Rowan, Erick Avelar,
Philippe Généreux, Paul Knaapen, Guus A de Waard, Gianluca Pontone, Daniele Andreini, Mouaz H AlMallah, Robert Jennings, Tami R Crabtree, Todd C Villines, James K Min, and Andrew D. Choi

This journal article is available at Health Sciences Research Commons: https://hsrc.himmelfarb.gwu.edu/
smhs_medicine_facpubs/5204

Coronary artery disease
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ABSTRACT

Objective The study evaluates the relationship of
coronary stenosis, atherosclerotic plaque characteristics
(APCs) and age using artificial intelligence enabled
quantitative coronary computed tomographic angiography
(AI-QCT).
To cite: Jonas R, Earls J,
Marques H, et al. Relationship of Methods This is a post-hoc analysis of data from
age, atherosclerosis and
303 subjects enrolled in the CREDENCE (Computed
angiographic stenosis using
TomogRaphic Evaluation of Atherosclerotic Determinants of
artificial intelligence. Open Heart
Myocardial IsChEmia) trial who were referred for invasive
2021;8:e001832. doi:10.1136/
coronary angiography and subsequently underwent
openhrt-2021-001832
coronary computed tomographic angiography (CCTA). In
this study, a blinded core laboratory analysing quantitative
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coronary angiography images classified lesions as
Accepted 8 October 2021
obstructive (≥50%) or non-obstructive (<50%) while AI
software quantified APCs including plaque volume (PV),
low-density non-calcified plaque (LD-NCP), non-calcified
plaque (NCP), calcified plaque (CP), lesion length on a
per-patient and per-lesion basis based on CCTA imaging.
Plaque measurements were normalised for vessel volume
and reported as % percent atheroma volume (%PAV) for
all relevant plaque components. Data were subsequently
stratified by age <65 and ≥65 years.
Results The cohort was 64.4±10.2 years and 29%
women. Overall, patients >65 had more PV and CP than
patients <65. On a lesion level, patients >65 had more
CP than younger patients in both obstructive (29.2 mm3
vs 48.2 mm3; p<0.04) and non-obstructive lesions (22.1
mm3 vs 49.4 mm3; p<0.004) while younger patients had
© Author(s) (or their
more %PAV (LD-NCP) (1.5% vs 0.7%; p<0.038). Younger
employer(s)) 2021. Re-use
patients had more PV, LD-NCP, NCP and lesion lengths in
permitted under CC BY-NC. No
commercial re-use. See rights
obstructive compared with non-obstructive lesions. There
and permissions. Published
were no differences observed between lesion types in
by BMJ.
older patients.
For numbered affiliations see
Conclusion AI-QCT identifies a unique APC signature
end of article.
that differs by age and degree of stenosis and provides
a foundation for AI-guided age-based approaches to
Correspondence to
Dr Andrew D Choi; a dchoi@mfa. atherosclerosis identification, prevention and treatment.
gwu.e du

Key questions
What is already known about this subject?
►► High-
risk atherosclerotic plaque characteristics

put patients at risk for cardiovascular events, but
is challenging for clinical practice using currently
available methods.

What does this study add?
►► This study provides a lesion-based assessment of

plaque changes by age.
►► This study provides support for use of artificial in-

telligence enabled quantitative coronary computed
tomographic angiography (AI-QCT) to identify an age
associated plaque phenotype.

How might this impact on clinical practice?
►► These findings provide clinicians with an opportunity

to tailor patient treatment based on the risk associated with a patient’s plaque profile.
►► These findings provide a basis for evaluating patients for enhanced prevention based on age with
AI-QCT.

INTRODUCTION
Coronary computed tomographic angiography (CCTA) has been validated as a non-
invasive imaging modality capable of both
ruling out coronary artery disease (CAD)
and quantifying coronary plaque.1 2 Advancements in the diagnostic specificity of CCTA
have allowed not only for quantification of
total plaque through the entirety of coronary
vascular anatomy, but also for the specific
identification and quantification of various
plaque characteristics in stable and unstable
lesions.3 This capability along with the use
of artificial intelligence (AI) and machine
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learning have resulted in an expanding foundation of
data describing high risk atherosclerotic plaque characteristics (APCs) that put specific patient populations at
increased risk for major adverse cardiovascular events
(MACE).4 Several APCs, namely, total plaque volume
(PV), low density non-calcified plaque (LD-NCP), non-
calcified plaque (NCP), calcified plaque (CP) and lesion
length have been identified as significant quantifiable
characteristics with prognostic value.5 6 The per cent
atheroma volume (PAV) reflects each APC’s quantity after
normalising for vessel volume and has been suggested as a
way of calculating and reporting APCs. Other significant
quantifiable markers included vascular positive remodelling (PR), spotty calcification (SC), napkin-ring sign and
high-risk plaque (HRP), defined as coronary lesions with
both LD-NCP and PR.5 7–9 There have been distinct differences in the characteristics of these plaques based on
various demographic and clinical variables, but whether
these characteristics vary by age is still being investigated.
This study intended to identify whether obstructive and
non-obstructive lesions have different plaque characteristics based on age, specifically in individuals older than
65 compared with those younger than 65 years through
plaque quantification using AI enabled quantitative coronary computed tomographic angiography (AI-QCT).

METHODS
The study population was comprised of the derivation
cohort of the Computed TomogRaphic Evaluation of
Atherosclerotic Determinants of Myocardial IsChEmia
(CREDENCE) trial (
ClinicalTrials.
gov, NCT02173275),
which was a prospective, multicentre diagnostic derivation–validation controlled clinical trial recruiting stable
patients from 2014 to 2017. Sites and Investigators are
listed in online supplemental appendix A. A detailed
design manuscript was previously published.10 Enrolled
patients underwent CCTA followed by invasive quantitative coronary angiography as the reference test within
60 days. Eligibility criteria included referral to non-
emergent invasive coronary angiography (ICA) based
on the American College of Cardiology/American
Heart Association clinical practice guidelines for stable
ischaemic heart disease. All index tests were interpreted
in blinded fashion by an imaging core laboratory. Patient
demographics, cardiovascular risk factors, laboratory
values and medications were prospectively collected and
recorded at the time of baseline and follow-up CCTAs.
CCTA imaging protocols
CCTA was performed using single or dual source CT
scanners of ≥64-detector rows. Sites performed CCTA in
accordance with the guidelines established by the Society
of Cardiovascular Computed Tomography (SCCT).11
Nitroglycerin was administered immediately prior to
CCTA to enhance imaging quality. Image quality for
CCTA was acceptable in 99% of patients.
2

AI enabled quantification of CCTA
The AI-based approach to CCTA interpretation in this
study was performed using a validated and US Food and
Drug Administration (FDA)-
cleared software service
(Cleerly Inc, New York, New York) that performs automated analysis of CCTA using a series of validated convolutional neural network models (including VGG19
network, 3D U-Net and VGG Network Variant) for image
quality assessment, coronary segmentation and labelling,
lumen wall evaluation and vessel contour determination
and plaque characterisation.12 13 The centerline algorithm
was developed from 1 007 945 images, which comprised
23 068 vessels from 3671 patients (online supplemental
appendix B). The lumen and vessel wall algorithms were
developed from 1 414 877 images, which comprised 8555
vessels from 3676 patients. First, the AI-aided approach
produces a centerline along each coronary artery, and
then for lumen and outer vessel wall contouring. This is
applied to each phase of the examination and the two
optimal series are identified for further analysis. After
establishing vessel wall contours, distance and volumetric
analyses were performed based on specified Hounsfield
unit (HU) cut offs for characterising plaque characteristics. After the AI algorithm has finished all operations,
as mandated by the FDA, a quality control cardiac CT
trained technician reviews the results of the AI analysis in
all cases with manual adjustment if necessary.
Coronary segments with a diameter ≥2 mm were
included in the analysis using the modified 18-segment
SCCT model.14 Each segment was evaluated for the presence or absence of coronary atherosclerosis, defined as any
tissue structure >1 mm2 within the coronary artery wall that
was differentiated from the surrounding epicardial tissue,
epicardial fat or the vessel lumen itself. The following APCs
were evaluated:
►► Atherosclerosis: Quantitative atherosclerosis characterisation was performed for every coronary artery
and its branches using the automated AI-
enabled
web-
based software platform (Cleerly Labs).13 PVs
(mm3) were calculated for each coronary lesion and
then summated to compute the PV at the patient
level. Plaque with a minimum volume of ≥3 mm3 was
included for analysis. This provided data for analysis
on both the lesion and patient level. PV was further
categorised using HU ranges with NCP defined as
30–350 HU; LD-NCP defined as plaques <30 HU; and
CP defined as >350 HU. Coronary plaque burden
was normalised to vessel volume to account for
natural variation in coronary artery volume. Plaque
burden was reported as PAV, CP PAV, NCP PAV and
LD-NCP PAV which was calculated as PV (by each
aforementioned type)/vessel volume×100%. Figure 1
provides an example of the software output for a
patient with an obstructive left anterior descending
(LAD) lesion predominantly comprised of NCP and
LD-NCP. Figure 2 reflects the AI generated analysis
of a non-obstructive LAD lesion comprised of NCP
Jonas R, et al. Open Heart 2021;8:e001832. doi:10.1136/openhrt-2021-001832
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Figure 1 A 39-year-old with coronary CT angiography (CCTA) undergoing artificial intelligence (AI)-aided evaluation of stenosis
and quantitative atherosclerosis burden. The patient demonstrates left anterior descending coronary artery obstructive stenosis
(82%) with a burden of plaque (352.5 mm3) consisting predominantly of non-calcified (321.8 mm3) that includes low-density
non-calcified plaque (LD-NCP 30.5 mm3). (A) shows a CCTA straight reformat with plaque identified, while (B) shows a straight
reformat with a colour overlay of non-calcified plaque (yellow), LD-NCP (red) and calcified plaque (blue). (C) shows a curved
multiplanar reformat. (D) shows a graphical output of the quantified plaque volume by AI-aided evaluation. dLAD, distal left
anterior descending; LM, left main; mLAD, mid left anterior descending; pLAD, proximal left anterior descending.

and LD-NCP while figure 3 provides an example of an
right coronary artery (RCA) lesion comprised mostly
of calcified plaque.

►►

Vascular remodelling: Arterial remodelling was calculated by examining the lesion diameter divided by the
normal reference diameter. PR was defined as a ratio

Figure 2 A 55-year-old with coronary CT angiography (CCTA) undergoing artificial intelligence (AI)-aided evaluation of stenosis
and quantitative atherosclerosis burden. The patient demonstrates left anterior descending coronary artery non-obstructive
stenosis (25%) with a burden of plaque (160.2 mm3) consisting predominantly of non-calcified (159.4 mm3) that includes non-
negligible low-density non-calcified plaque (8 mm3). (A) shows a CCTA straight reformat with plaque identified, while (B) shows
a straight reformat with a colour overlay of non-calcified plaque (yellow). (C) shows a curved multiplanar reformat. (D) shows a
graphical output of the quantified plaque volume by AI-aided evaluation. dLAD, distal left anterior descending; LM, left main;
mLAD, mid left anterior descending; pLAD, proximal left anterior descending.
Jonas R, et al. Open Heart 2021;8:e001832. doi:10.1136/openhrt-2021-001832
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Figure 3 A 74-year-old with coronary CT angiography (CCTA) undergoing artificial intelligence (AI)-aided evaluation of stenosis
and quantitative atherosclerosis burden. The patient demonstrates right coronary artery obstructive stenosis (61%) with a high
burden of plaque (796.8 mm3) consisting predominantly of calcified plaque (550.8 mm3). (A) shows a CCTA straight reformat
with plaque identified, while (B) shows a straight reformat with a colour overlay of non-calcified plaque (yellow), and calcified
plaque (blue). (C) shows a curved multiplanar reformat. (D) shows a graphical output of the quantified plaque volume by AI-
aided evaluation. dLAD, distal left anterior descending; LM, left main; mLAD, mid left anterior descending; pLAD, proximal left
anterior descending.

►►
►►

≥1.10, negative remodelling was defined as a ratio
of <0.95 and intermediate remodelling was a ratio
between 0.95 and 1.10.15
HRP: HRPs were defined as coronary lesions with
both LD-NCP and PR.7
Other APCs: Plaque length measured uninterrupted
plaque along the length of a vessel. Plaque diffusivity
was the percent plaque along the length of a vessel
divided by the total vessel length.16

Quantitative coronary angiography
Quantitative coronary angiography (QCA) was performed
by a blinded core laboratory using an automated edge-
detection algorithm by standard approaches as previously
reported.17 Angiographic percent diameter stenosis, and
lumen diameters of the proximal and distal reference
segments were measured.
Statistical analysis
All statistical analyses were performed using SAS V.9.4
(SAS, Cary, North Carolina). Continuous data are
reported as mean±SD, and categorical variables are
presented as absolute numbers with corresponding
frequencies. Student’s t-test, Mann-Whitney test, χ2 and
Fisher exact tests were used to compare the distribution
of continuous and categorical variables, respectively.
4

Patient and public involvement statement
This is a retrospective study that analyses prospectively collected de-identified multicentre data from the
CREDENCE trial. Patients were recruited and consented
for participation in the CREDENCE trial, but were not
interactive with investigators conducting the substudy
analysis. However, patients were involved in the design
of the study to the extent that their invasive and non-
invasive imaging was used to conduct this substudy, and
study findings are aimed at improving clinical knowledge
of cardiac disease in their cohort.
RESULTS
The study cohort was comprised of 303 patients whose
mean age was 64.4±10.2 years. The cohort was 29% women,
71% Asian and had a high prevalence of CAD risk factors
including 64% with hypertension, 45% with dyslipidaemia
and 48% with prior tobacco use (table 1). Nearly half of
the patients (48%) demonstrated typical or atypical angina,
while over one-
third (35%) were asymptomatic. When
stratifying by QCA there were significantly more women
with non-obstructive (<50%) CAD (39% vs 22% p=0.001).
Patients with obstructive stenosis (≥50%) were significantly
more likely than patients with non-obstructive stenosis to
have a family history of CAD and to have used tobacco, with
Jonas R, et al. Open Heart 2021;8:e001832. doi:10.1136/openhrt-2021-001832
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Table 1 Baseline demographics
Non-obstructive
(<50%) (n=128)

All (n=303)
Age, years, mean (SD)
Female

64.4 (10.2)
88 (29%)

Obstructive (≥50%)
(n=175)

64.3 (10.2)
50 (39%)

64.6 (10.2)
38 (22%)

P value
0.8
0.001

Hypertension

195 (64%)

79 (62%)

116 (66%)

0.41

Dyslipidaemia

135 (45%)

56 (44%)

79 (45%)

0.81

Diabetes

95 (31%)

38 (30%)

57 (33%)

0.59

Family history

59 (20%)

18 (14%)

41 (23%)

0.04

146 (48%)

53 (41%)

93 (53%)

0.04

109 (36%)

36 (28%)

73 (42%)

0.11

49 (16%)

23 (18%)

26 (15%)

40 (13%)
105 (35%)

19 (15%)
50 (39%)

21 (12%)
55 (31%)

Tobacco use
Symptoms
 Typical angina
 Atypical
 Non-cardiac
 Asymptomatic

no differences noted for prevalence of hypertension, dyslipidaemia or diabetes (table 2). Among younger (age <65)
versus older patients (age ≥65), hypertension was more
commonly observed in older than younger patients (74%
vs 53%). There were no significant differences in gender
composition, dyslipidaemia, diabetes or symptoms between
younger and older individuals.
Table 3 summarises CCTA findings evaluated by AI as
obstructive (<50%) and obstructive
a function of non-
(≥50%) stenosis by QCA for patients <65 and ≥65 on a
patient basis. In patients with both non-
obstructive
per-
(<50%) and obstructive stenosis, patients ≥65 had overall
significantly greater plaque volume, total plaque %PAV,
and calcified plaque when compared with patients <65. In
examining specific APCs, older patients had overall higher
PV (792.7±486.1 mm3 vs 500.1+349.8 mm3; p<0.0001) across

plaque components including higher calcified plaque
(366.5±336.2 mm3 vs 148.0±187.5 mm3; p<0.0001) and
calcified %PAV (4.6% vs 2.6%; p=0.01). However, younger
patients with non-
obstructive disease demonstrated a
similar degree of NCP (243.0±220.2 mm3 vs 286.5±190.2
mm3; p=NS) and LD-NCP (8.6±11.1 mm3 vs 8.9±12.9 mm3;
p=NS) when compared with older patients. Obstructive
lesions in patients >65 had higher PAV of calcified (8.1%
vs 3.2%; p<0.0001); and NCP (9.1% vs 7.6%; p=0.007) than
younger patients with obstructive lesions (table 3).
Further evaluating APCs on an individual lesion basis,
table 4 shows the PV by AI-
QCT of individual non-
obstructive lesions was greater in patients ≥65 versus
patients <65 (105.6 mm3 vs 60.5 mm3; p<0.005). However,
non-obstructive lesions in patients <65 exhibit a greater
proportion of %PAV (LD-NCP) (1.5% vs 0.7%; p=0.038),

Table 2 Demographics of patients with non-obstructive stenoses and obstructive stenosis by age
Non-obstructive (<50%) (N=128) Obstructive (≥50%) (N=175)
Variable, n (%)
Age, years, mean
(SD)
Female

Age <65
(N=139)

Age ≥65
(N=164)

P value

Age <65
(N=62)

Age ≥65
(N=66)

P value

Age <65
(N=77)

Age ≥65
(N=98)

P value

55.7 (7)

71.9 (5)

<0.001

56.1 (7)

71.9 (6)

<0.0001

55.3 (7)

71.8 (5)

<0.0001

36 (26)

52 (32)

0.27

23 (37)

27 (41)

0.66

13 (17)

25 (26)

0.17

Hypertension

74 (53)

121 (74)

<0.0001

33 (53)

46 (70)

0.05

41 (53)

75 (77)

0.001

Dyslipidaemia

56 (40)

79 (48)

0.17

24 (39)

32 (49)

0.26

32 (42)

47 (48)

0.40

Diabetes

38 (27)

57 (35)

0.17

17 (27)

21 (32)

0.59

21 (27)

36 (37)

0.18

Family history

35 (25)

24 (15)

0.02

13 (21)

5 (8)

0.03

22 (29)

19 (19)

0.15

Tobacco use

75 (54)

71 (43)

0.06

26 (42)

27 (41)

0.90

49 (64)

44 (45)

0.01

 Typical angina

52 (37)

57 (35)

18 (29)

18 (27)

34 (44)

39 (40)

 Atypical

25 (18)

24 (14)

10 (16)

13 (20)

15 (20)

11 (11)

 Non-cardiac
 Asymptomatic

13 (9)
49 (32)

27 (16)
56 (34)

9 (15)
25 (40)

10 (15)
25 (38)

4 (5)
24 (31)

17 (17)
31 (32)

Symptoms

0.31

0.95
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Table 3 Per-patient adverse plaque characteristics by artificial intelligence enabled quantitative coronary computed
tomographic angiography by non-obstructive versus obstructive angiographic stenosis stratified by age
Non-obstructive (<50%) per-patient
(N=128)

Obstructive (≥50%) per-patient
(N=175)

Age <65
(N=62)

Age ≥65
(N=66)

P value

Age <65
(N=77)

Age ≥65
(N=98)

P value

PV, mm
LD-NCP, mm3

357.5 (379.3)
8.6 (11.1)

510.7 (206.2)
8.9 (12.9)

0.02
0.46

500.1 (349.8)
15.0 (15.3)

792.7 (486.1)
12.4 (15.8)

<0.0001
0.11

NCP, mm3

243.0 (220.2)

286.5 (190.2)

0.10

352.1 (266.8)

426.2 (262.7)

0.02

114.5 (190.5)

224.2 (372.1)

0.007

148.0 (187.5)

366.5 (336.2)

<0.0001

Total plaque %PAV

8.2 (7.3)

11.1 (8.6)

0.03

10.7 (6.9)

17.2 (9.7)

<0.0001

LD-NCP %PAV

0.2 (0.2)

0.2 (0.3)

0.41

0.3 (0.3)

0.2 (0.2)

0.07

Variable, mean (SD)
3

CP, mm

3

NCP %PAV

5.6 (4.4)

6.5 (4.0)

0.14

7.6 (5.1)

9.1 (4.7)

0.007

CP %PAV

2.6 (3.6)

4.6 (6.2)

0.01

3.2 ((4.0)

8.1 (7.0)

<0.0001

% plaque calcified

25.3 (21.3)

33.9 (22.4)

0.21

26.6 (21.3)

42.5 (20.5)

<0.0001

Remodelling index

1.30 (0.20)

1.35 (0.21)

0.50

1.38 (0.23)

1.40 (0.22)

0.44

Positive remodelling >1.1, n (%)

48 (79)

55 (83)

0.56

67 (88)

88 (90)

0.73

Intermediate remodelling, n (%)

10 (16)

10 (15)

9 (12)

10 (10)

3 (5)

1 (2)

43 (69)
23.5 (13.7)

51 (77)
31.9 (21.1)

Negative remodelling, n (%)
HRP (LD-NCP +PR), n (%)
Lesion length, mm

0
0.31
0.02

61 (79)
28.7 (14.8)

0
79 (81)
37.6 (19.6)

0.82
<0.001

CP, calcified plaque; HRP, high risk plaque; LD-NCP, low-density non-calcified plaque; NCP, non-calcified plaque; %PAV, percent atheroma
volume; PR, positive remodelling ; PV, plaque volume.

Table 4 Per-lesion adverse plaque characteristics by artificial intelligence enabled quantitative coronary computed
tomographic angiography by non-obstructive versus obstructive angiographic stenosis stratified by age
Non-obstructive (<50%) per-lesion

Obstructive (≥50%) per-lesion

Age <65
(N=71)

Age ≥65
(N=116)

P value

Age <65
(N=77)

Age ≥65
(N=98)

P value

PV, mm
LD-NCP, mm3

60.5 (79.8)
1.6 (3.1)

105.6 (140.5)
2.0 (6.6)

0.001
0.56

103.8 (134.5)
4.2 (8.2)

109.7 (131.4)
2.6 (10.0)

0.83
0.26

NCP, mm3

38.4 (50.8)

56.2 (75.8)

0.058

74.6 (108.1)

61.5 (85.8)

0.33

CP, mm3

22.1 (39.1)

49.4 (86.8)

0.004

29.2 (51.5)

48.2 (72.7)

0.04

PAV (total plaque)

41.0 (17.4)

44.8 (16.8)

0.17

49.9 (18.6)

54.7 (16.5)

0.07

% PAV (LD-NCP)

1.5 (3.3)

0.7 (1.3)

0.038

2.0 (3.0)

1.2 (2.8)

0.12

% PAV (NCP)

25.6 (12.4)

25.2 (12.9)

0.81

33.1 (19.3)

30.5 (15.4)

0.32

% PAV (CP)

13.7 (15.7)

18.6 (18.1)

0.07

13.9 (15.6)

30.5 (15.4)

0.001

% Plaque calcified

28.0 (28.5)

36.8 (28.9)

0.06

27.3 (26.8)

38.2 (27.3)

0.007

Variable
3

Remodelling index

1.13 (0.20)

1.06 (0.21)

Positive remodeling >1.1

29 (41%)

34 (29%)

Intermediate remodelling

28 (39%)

46 (40%)

Negative remodelling

14 (20%)

36 (31%)

HRP (LD-NCP +PR)
Lesion length, mm

34 (48%)
13.9 (10.4)

42 (36%)
18.1 (15.6)

0.02
0.36

0.16
0.02

1.10 (0.28)

1.05 (0.28)

25 (33%)

29 (30%)

26 (34%)

27 (28%)

26 (34%)

42 (43%)

31 (40%)
18.3 (15.5)

33 (34%)
18.2 (15.1)

0.24
0.78

0.40
0.90

CP, calcified plaque; HRP, high risk plaque; LD-NCP, low-density non-calcified plaque; NCP, non-calcified plaque; PAV, per cent atheroma
volume; PR, positive remodelling ; PV, plaque volume.
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near significantly higher volume of NCP in age <65 (38.4
mm3 vs 56.2 mm3; p<0.058), as well as a higher remodelling index (1.13 vs 1.06; p=0.02) with shorter lesion
length (13.9 mm vs 18.1 mm; p=0.02). An illustrative case
of obstructive stenosis in a 39-year-old with high NCP and
LD-NCP burden is shown in figure 1. An illustrative case
of non-obstructive stenosis in a 55-year-old with high NCP
is shown in figure 2. Age >65 patients with non-obstructive
lesions exhibit higher calcified plaque (49.4 mm3 vs 22.1
mm3; p=0.004) and near significant % plaque calcified
(36.8% vs 28.0%; p=0.06) compared with patient <65. An
illustrative case of calcified plaque in a 74-year-old with
high calcified burden is shown in figure 3.
Online supplemental appendix C shows per-
patient
and per-lesion analysis within the younger and older age
cohorts for non-
obstructive and obstructive stenoses. In
both younger and older individuals, PV and CP are higher
for obstructive stenosis versus non-obstructive stenosis. In
older adults, there was no difference between the volume
of LD-
NCP in non-
obstructive and obstructive lesions,
while calcified plaque was significantly higher in obstructive versus non-obstructive lesions (366.5 mm3 vs 224 mm3;
p=0.01).
DISCUSSION
In this analysis of CREDENCE, we uniquely applied AI for
quantitative plaque evaluation and add several important
new observations to the expanding body of literature on
APC identified by CCTA. Our study found that APCs of
high-grade stenoses differ by age with patients <65 years
exhibiting greater PV, LD-NCP, NCP and lesion length
in obstructive lesions compared with non-
obstructive
lesions. Patients >65 years exhibited a greater burden of
calcified plaque in both non-obstructive and obstructive
stenoses. Furthermore, in patients >65 with obstructive
stenosis, while there was a higher calcified and NCP
burden, younger patients had similar LD-NCP as older
patients with obstructive lesions.
Recent validation of the AI-guided approach applied
in this study allows for accurate AI evaluation of stenosis
as well allowing for quantification of PV to an order of
3–5 mm3 that may not be readily identified by expert
readers.12 18 19 This data extends atherosclerosis evaluation beyond previous logistic regression models incorporating plaque as one of many variables defined by manual
methods.20 In addition, the use of well-validated deep
machine learning approaches allows for enhanced and
rapid image processing. Previous validation data from
our group has shown that this AI approach can perform
whole heart atherosclerosis and stenosis evaluation in
approximately 10 min, whereas manual approaches may
take several hours to complete and be prone to variability.
Through this AI approach, we show that atherosclerosis in younger adults with non-
obstructive stenoses
demonstrate comparable plaque characterisation when
compared with older adults. This includes the presence
of high-risk plaque features such as NCP, LD-NCP and
Jonas R, et al. Open Heart 2021;8:e001832. doi:10.1136/openhrt-2021-001832

PR that qualitatively portend, by SCCT expert consensus,
a future risk of cardiovascular events.21 Importantly, AI
identified a higher PAV of LD-NCP in younger individuals
with non-obstructive atherosclerosis, a plaque type identified as highest risk by cardiac CT.22 These data affirm
prior findings that younger patients have high volumes
of non-calcified atherosclerosis with a higher degree of
LD-NCP, while older patients develop a higher degree of
calcified plaque in both non-obstructive and obstructive
lesions.22 Lowenstern et al’s subanalysis of the PROMISE
(Prospective Multicenter Imaging Study for Evaluation
of Chest Pain) study also supports the finding that older
patients have more calcified plaque.23 However, importantly, the study also showed that high calcium scores
did not confer risk for MACE in older patients while it
did conferred risk for MACE in individuals younger than
65.23 The study does not comment on additional APCs
like LD-NCP, but remains consistent with our findings
and re-emphasises the benefit of addressing plaque characteristics for prognostication for MACE at different ages.
In our study, age stratification identified differences in
overall plaque burden, which may help identify younger
patients who may be at risk for future acute coronary
syndrome (ACS) despite having non-obstructive stenoses.
While the literature on APCs and high-risk lesion assessment is rapidly expanding, there is still limited information regarding age-oriented plaque composition. In
particular, identifying which younger adults are at risk for
CAD remains challenging due to limitations in current
risk calculators and insufficient data in this group.24 Additionally, limitations exist in identifying atherosclerosis via
conventional approaches, such as stress testing, making
younger adults less likely to be treated with preventive
therapies. While Ruiz-García et al published a substudy
of the PROSPECT (Prospective Natural History Study of
Coronary Atherosclerosis) trial evaluating APCs of non-
culprit lesions via intravascular ultrasound (IVUS) that
concluded that patients older than 65 had greater plaque
burden, necrotic core and dense calcium content than
patients younger than 65 (regardless of gender),25 this
study involved non-culprit lesions in patients who had
already experienced ACS and could not be generalised to
a younger population in the preventive stages of disease.
In the CCTA literature, an age-based study was recently
conducted by Conte et al who evaluated a subgroup of
patients from the ICONIC (Incident Coronary Syndromes
Identified by Computed Tomography) trial to determine
whether APCs of culprit lesions varied by age and showed
that older patients had greater total PV, specifically calcified plaque, as well as greater segment involvement and
segment severity scores than younger patients.26 However,
again, the study cohort was comprised of ACS patients and
the lesion level analysis pertained specifically to culprit
lesions, limiting the ability to generalise findings. Additionally, Kim et al initiated a substudy of the PARADIGM
(Progression of AtheRosclerotic PlAque DetermIned by
Computed TomoGraphic Angiography Imaging) trial, a
cohort with suspected or known CAD, and showed that
7
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the rate of plaque progression, specifically densely calcified
plaque, increased with age.27 The study’s intention was to
identify gross trends in a middle-aged cohort (40–75 years),
and to that end, whole heart plaque was evaluated while
lesion-based changes were unaddressed.
While calcified plaque increases with age, a finding
consistent with our data, this does not account for the
high risk ACPs at younger ages that may be important for
early screening.24 28 Our study findings suggest that the
quantification of APCs associated within plaque identified by AI-QCT, namely, LD-NCP, NCP and PV and lesion
length may also provide prognostic value when screening
patients <65 years. Understanding this plaque phenotype
also may allow for enhanced opportunities to understand
and modulate the plaque phenotype through preventive
therapies such as statins and newer agents such as PCSK-9
inhibition.29
This study is subject to limitations. While patients were
enrolled prospectively from a large, multicentre clinical
trial with evaluation by a blinded core laboratory, the evaluation was post hoc and not powered to detect differences in
plaque types. About one-third of the patients had demonstrable atherosclerosis despite the absence of symptoms,
which may not be fully representative of a stable chest
pain population, but also represent a limitation in current
guidelines for testing. Additionally, the CCTAs evaluated
reflect a single point in time rather than a longitudinal
period thereby limiting knowledge of plaque progression
as reflected at various ages. Though coronary lesions are
dynamic, changes in PV composition as a function of worsening stenosis severity was not evaluated. Finally, we used
angiographic coronary stenosis as a marker of CAD severity.
While large-scale prognosis of AI-QCT defined quantitative
plaque composition has not yet been performed, it remains
the subject of future study in the upcoming CONFIRM2
study (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry;
NCT04279496).
In sum, AI-QCT identifies a unique APC signature that
differs by age with patients <65 years exhibiting greater PV,
LD-NCP, NCP and lesion length in obstructive compared
with non-obstructive lesions. While no difference in plaque
composition was observed in obstructive stenoses for
patients >65 years, older patients had greater CP volume
and patients <65 had more NCP and LD-
NCP. These
findings have important implications for prognosticating
younger and older adults with unique plaque phenotypes
identified by AI-QCT that allows a foundation for AI-guided
precision approaches to cardiovascular prevention.
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